Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lowe...

Full description

Saved in:
Bibliographic Details
Published inBlood advances Vol. 2; no. 16; pp. 2079 - 2089
Main Authors Itzykson, Raphael, Crouch, Simon, Travaglino, Erica, Smith, Alex, Symeonidis, Argiris, Hellström-Lindberg, Eva, Sanz, Guillermo, Čermák, Jaroslav, Stauder, Reinhard, Elena, Chiara, Germing, Ulrich, Mittelman, Moshe, Langemeijer, Saskia, Mądry, Krzysztof, Tatic, Aurelia, Holm, Mette Skov, Almeida, Antonio Medina, Savic, Aleksandar, Šimec, Njetočka Gredelj, Luño, Elisa, Culligan, Dominic, Guerci-Bresler, Agnes, Malcovati, Luca, van Marrewijk, Corine, Bowen, David, de Witte, Theo, Fenaux, Pierre
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 28.08.2018
American Society of Hematology
Elsevier
Subjects
Myeloid Neoplasia
Online AccessGet full text
ISSN2473-9529
2473-9537
2473-9537
DOI10.1182/bloodadvances.2018020495

Cover

Abstract Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark − count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10−4), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P < 10−4). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860. •A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS.•Platelet drop combined with RBC-TD at 6 months provides an inexpensive and validated classifier of outcome in lower-risk MDS. [Display omitted]
AbstractList Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark - count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10-4), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P < 10-4). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark - count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10-4), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P < 10-4). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.
A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS. Platelet drop combined with RBC-TD at 6 months provides an inexpensive and validated classifier of outcome in lower-risk MDS. Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark − count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10 −4 ), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively ( P < 10 −4 ). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.
Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark - count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, < 10 ), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively ( < 10 ). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.
Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark − count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10−4), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P < 10−4). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.
A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS. Platelet drop combined with RBC-TD at 6 months provides an inexpensive and validated classifier of outcome in lower-risk MDS.
Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 ± 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark − count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets >25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop ≤25%, P < 10−4), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop >25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop >25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P < 10−4). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop >25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860. •A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS.•Platelet drop combined with RBC-TD at 6 months provides an inexpensive and validated classifier of outcome in lower-risk MDS. [Display omitted]
Author Mądry, Krzysztof
Itzykson, Raphael
Stauder, Reinhard
Luño, Elisa
Elena, Chiara
Guerci-Bresler, Agnes
de Witte, Theo
Hellström-Lindberg, Eva
Crouch, Simon
Fenaux, Pierre
Travaglino, Erica
Smith, Alex
Holm, Mette Skov
Malcovati, Luca
Bowen, David
Symeonidis, Argiris
Sanz, Guillermo
Mittelman, Moshe
Savic, Aleksandar
van Marrewijk, Corine
Langemeijer, Saskia
Culligan, Dominic
Šimec, Njetočka Gredelj
Tatic, Aurelia
Almeida, Antonio Medina
Čermák, Jaroslav
Germing, Ulrich
Author_xml – sequence: 1
  givenname: Raphael
  orcidid: 0000-0003-2139-6262
  surname: Itzykson
  fullname: Itzykson, Raphael
  email: raphael.itzykson@aphp.fr
  organization: Département d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris Diderot, Paris, France
– sequence: 2
  givenname: Simon
  surname: Crouch
  fullname: Crouch, Simon
  organization: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom
– sequence: 3
  givenname: Erica
  surname: Travaglino
  fullname: Travaglino, Erica
  organization: Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
– sequence: 4
  givenname: Alex
  surname: Smith
  fullname: Smith, Alex
  organization: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom
– sequence: 5
  givenname: Argiris
  surname: Symeonidis
  fullname: Symeonidis, Argiris
  organization: Division Hematology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece
– sequence: 6
  givenname: Eva
  surname: Hellström-Lindberg
  fullname: Hellström-Lindberg, Eva
  organization: Division Hematology, Department of Medicine, Karolinska Institute, Stockholm, Sweden
– sequence: 7
  givenname: Guillermo
  surname: Sanz
  fullname: Sanz, Guillermo
  organization: Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
– sequence: 8
  givenname: Jaroslav
  surname: Čermák
  fullname: Čermák, Jaroslav
  organization: Department of Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic
– sequence: 9
  givenname: Reinhard
  surname: Stauder
  fullname: Stauder, Reinhard
  organization: Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
– sequence: 10
  givenname: Chiara
  surname: Elena
  fullname: Elena, Chiara
  organization: Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
– sequence: 11
  givenname: Ulrich
  surname: Germing
  fullname: Germing, Ulrich
  organization: Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
– sequence: 12
  givenname: Moshe
  surname: Mittelman
  fullname: Mittelman, Moshe
  organization: Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center, Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel
– sequence: 13
  givenname: Saskia
  surname: Langemeijer
  fullname: Langemeijer, Saskia
  organization: Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
– sequence: 14
  givenname: Krzysztof
  surname: Mądry
  fullname: Mądry, Krzysztof
  organization: Department of Haematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
– sequence: 15
  givenname: Aurelia
  surname: Tatic
  fullname: Tatic, Aurelia
  organization: Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
– sequence: 16
  givenname: Mette Skov
  surname: Holm
  fullname: Holm, Mette Skov
  organization: Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
– sequence: 17
  givenname: Antonio Medina
  surname: Almeida
  fullname: Almeida, Antonio Medina
  organization: Department of Hematology, Hospital da Luz, Lisbon, Portugal
– sequence: 18
  givenname: Aleksandar
  surname: Savic
  fullname: Savic, Aleksandar
  organization: Clinic of Hematology–Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
– sequence: 19
  givenname: Njetočka Gredelj
  surname: Šimec
  fullname: Šimec, Njetočka Gredelj
  organization: Division of Hematology, Department of Internal Medicine, Merkur University Hospital, Zagreb, Croatia
– sequence: 20
  givenname: Elisa
  surname: Luño
  fullname: Luño, Elisa
  organization: Servicio d'Hematología. Hospital Universitario Central de Asturias, Oviedo, Spain
– sequence: 21
  givenname: Dominic
  surname: Culligan
  fullname: Culligan, Dominic
  organization: Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
– sequence: 22
  givenname: Agnes
  surname: Guerci-Bresler
  fullname: Guerci-Bresler, Agnes
  organization: Service d'Hématologie, Centre Hospitalier Universtaire Brabois Vandoeuvre, Nancy, France
– sequence: 23
  givenname: Luca
  surname: Malcovati
  fullname: Malcovati, Luca
  organization: Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
– sequence: 24
  givenname: Corine
  surname: van Marrewijk
  fullname: van Marrewijk, Corine
  organization: Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
– sequence: 25
  givenname: David
  surname: Bowen
  fullname: Bowen, David
  organization: St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom
– sequence: 26
  givenname: Theo
  surname: de Witte
  fullname: de Witte, Theo
  organization: Department of Tumor Immunology–Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
– sequence: 27
  givenname: Pierre
  surname: Fenaux
  fullname: Fenaux, Pierre
  organization: Département d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris Diderot, Paris, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30126931$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:142611425$$DView record from Swedish Publication Index
BookMark eNqNkk1vFDEMhkeoiJbSv4DmyGVKPiaZzAUBVYFKlbjAhUuUSTzbdLPJkmS2mn9P2t22bE97imO_fmzLflsd-eChqmqMzjEW5OPgQjDKbJTXkM4JwgIR1PbsVXVC2o42PaPd0ZNN-uPqLKVbhBDuOGU9eVMdU4QJ7yk-qf5cqujmeu1UBge51mHyuV5aD9nqVN-oVK9jWPiQyr_eKDdBbX3twh3EJtq0rFczuGDmVBAPmjR7E8MK0rvq9ahcgrPde1r9_nb56-JHc_3z-9XFl-tGd4jnpu0Vo4NgnBpKhBk0Ggkhpu2MoJ1BtIyHOBNYEyZAMMCEqnbkGAktxgErelpdbbkmqFu5jnal4iyDsvLBEeJCqlg6cyBbQwfFSdci1LUdtIJwphgHKFQYyFBYzZaV7mA9DXu0nWtZrEISHHNe9J-2-hJZgdHgc1RuL20_4u2NXISN5BhTjlgBfNgBYvg7QcpyZZMG55SHMCVJUF8G7nnfFen7_2s9FXlc5nMzOoaUIoxS26yyDfelrZMYyfsDknsHJJ8PqADEC8BjjQNSv25ToWx6YyHKpC0UlbERdC6rsIdAPr-AaGe91cotYT4M8Q-0-v6D
CitedBy_id crossref_primary_10_1002_hon_2777
crossref_primary_10_3390_cancers15082248
crossref_primary_10_17650_1818_8346_2022_17_4_106_117
crossref_primary_10_1007_s00277_024_05925_3
crossref_primary_10_1007_s10238_022_00985_z
crossref_primary_10_3324_haematol_2020_266817
crossref_primary_10_1002_hem3_70073
crossref_primary_10_2139_ssrn_4114950
crossref_primary_10_1016_j_clml_2022_05_001
crossref_primary_10_1016_j_isci_2022_104931
crossref_primary_10_1016_j_leukres_2021_106543
crossref_primary_10_1038_s41375_020_0967_x
crossref_primary_10_7889_tct_21_017
crossref_primary_10_1007_s00277_021_04608_7
crossref_primary_10_1080_17474086_2022_2029698
crossref_primary_10_2298_MPNS22S1038S
crossref_primary_10_3390_cancers14081941
crossref_primary_10_1111_trf_16093
crossref_primary_10_1182_hematology_2021000277
Cites_doi 10.1111/j.1365-2141.2011.08893.x
10.1038/sj.leu.2405070
10.1007/s11135-006-9018-6
10.1109/TAC.1974.1100705
10.1111/j.1600-0609.2009.01299.x
10.1182/blood-2012-03-420489
10.1200/JCO.2012.45.5626
10.1182/blood.V89.6.2079
10.1200/JCO.2009.25.0654
10.1093/jnci/djj129
10.1182/blood-2002-04-1199
10.1002/sim.4780050306
10.1007/s00277-016-2649-3
10.1002/sim.4780131603
10.1038/leu.2015.295
10.1200/JCO.2009.25.2395
10.1200/JCO.2007.15.5770
10.1111/bjh.13450
10.1371/journal.pone.0180756
10.1080/01621459.1999.10474144
10.1007/s00277-017-3009-7
10.1200/JCO.2005.01.7038
10.1093/ajcp/90.3.262
10.1111/bjh.13008
10.18637/jss.v033.i01
10.1200/JCO.2006.08.5696
10.1200/JCO.2011.40.7379
10.1055/s-0037-1613840
10.1002/cncr.24984
10.1002/ajh.21959
ContentType Journal Article
Copyright 2018 American Society of Hematology
2018 by The American Society of Hematology.
2018 by The American Society of Hematology 2018
Copyright_xml – notice: 2018 American Society of Hematology
– notice: 2018 by The American Society of Hematology.
– notice: 2018 by The American Society of Hematology 2018
CorporateAuthor on behalf of the European MDS Registry members
European MDS Registry members
CorporateAuthor_xml – name: on behalf of the European MDS Registry members
– name: European MDS Registry members
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
DOA
DOI 10.1182/bloodadvances.2018020495
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Freely available online
SwePub Articles full text
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2473-9537
EndPage 2089
ExternalDocumentID oai_doaj_org_article_4d3ba627400747e48265a56eee12eb2b
oai_swepub_ki_se_486166
PMC6113605
30126931
10_1182_bloodadvances_2018020495
S2473952920308855
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID .1-
.FO
0R~
53G
AALRI
AAXUO
AAYWO
ACVFH
ADCNI
ADVLN
AEUPX
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
EBS
FDB
GROUPED_DOAJ
H13
HYE
OK1
ROL
RPM
THE
W2D
Z5R
AFCTW
AAYXX
CITATION
NPM
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
ID FETCH-LOGICAL-c706t-49a53b8563d328dbc0f222d47d837d0318006581c258e85e123a4f6108c8fb1a3
IEDL.DBID DOA
ISSN 2473-9529
2473-9537
IngestDate Wed Aug 27 01:30:10 EDT 2025
Wed Sep 24 03:38:13 EDT 2025
Thu Aug 21 14:14:52 EDT 2025
Fri Sep 05 07:10:01 EDT 2025
Thu Apr 03 07:00:05 EDT 2025
Thu Apr 24 23:05:25 EDT 2025
Tue Jul 01 02:14:17 EDT 2025
Fri Feb 23 02:45:53 EST 2024
Tue Aug 26 16:31:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Language English
License This is an open access article under the CC BY-NC-ND license.
2018 by The American Society of Hematology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c706t-49a53b8563d328dbc0f222d47d837d0318006581c258e85e123a4f6108c8fb1a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ORCID 0000-0003-2139-6262
OpenAccessLink https://doaj.org/article/4d3ba627400747e48265a56eee12eb2b
PMID 30126931
PQID 2091239697
PQPubID 23479
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_4d3ba627400747e48265a56eee12eb2b
swepub_primary_oai_swepub_ki_se_486166
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6113605
proquest_miscellaneous_2091239697
pubmed_primary_30126931
crossref_citationtrail_10_1182_bloodadvances_2018020495
crossref_primary_10_1182_bloodadvances_2018020495
elsevier_sciencedirect_doi_10_1182_bloodadvances_2018020495
elsevier_clinicalkey_doi_10_1182_bloodadvances_2018020495
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-08-28
PublicationDateYYYYMMDD 2018-08-28
PublicationDate_xml – month: 08
  year: 2018
  text: 2018-08-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington, DC
PublicationTitle Blood advances
PublicationTitleAlternate Blood Adv
PublicationYear 2018
Publisher Elsevier Inc
American Society of Hematology
Elsevier
Publisher_xml – name: Elsevier Inc
– name: American Society of Hematology
– name: Elsevier
References Malcovati, Porta, Pascutto (bib12) 2005; 23
Akaike (bib15) 1974; 19
Ibrahim, Chu, Chen (bib32) 2010; 28
Pellagatti, Benner, Mills (bib5) 2013; 31
Vardiman, Harris, Brunning (bib10) 2002; 100
Korn (bib13) 1986; 5
Dayyani, Conley, Strom (bib25) 2010; 116
Fine, Gray (bib14) 1999; 94
Ross, Ayscue, Watson, Bentley (bib21) 1988; 90
Friedman, Hastie, Tibshirani (bib18) 2010; 33
Sekeres, Maciejewski, Giagounidis (bib27) 2008; 26
Goldberg, Chen, Corral (bib23) 2010; 28
Pereira, Nomdedeu, Aguilar (bib30) 2011; 86
Malcovati, Germing, Kuendgen (bib6) 2007; 25
Petrylak, Ankerst, Jiang (bib8) 2006; 98
Grambsch, Louis, Bostick (bib16) 1994; 13
van der Helm, Alhan, Wijermans (bib28) 2011; 155
Buckley, James, Brown (bib20) 2000; 83
Montillo, Hamblin, Hallek, Montserrat, Morra (bib7) 2005; 90
de Swart, Smith, MacKenzie (bib11) 2017; 96
Costongs, Janson, Bas, Hermans, Brombacher, van Wersch (bib19) 1985; 23
Bejar, Stevenson, Caughey (bib4) 2012; 30
Garcia-Manero, Shan, Faderl (bib22) 2008; 22
Nachtkamp, Stark, Strupp (bib24) 2016; 95
Alhan, Westers, Cremers (bib3) 2016; 30
de Swart, Smith, Johnston (bib9) 2015; 170
Greenberg, Cox, LeBeau (bib1) 1997; 89
Zhao, Catalano, DeGruttola, Michor (bib31) 2017; 12
Neukirchen, Blum, Kuendgen (bib26) 2009; 83
Greenberg, Tuechler, Schanz (bib2) 2012; 120
O'Brien (bib17) 2007; 41
Zeidan, Lee, Prebet (bib29) 2014; 167
Friedman (2019111617252500700_B18) 2010; 33
Malcovati (2019111617252500700_B6) 2007; 25
Montillo (2019111617252500700_B7) 2005; 90
de Swart (2019111617252500700_B11) 2017; 96
Korn (2019111617252500700_B13) 1986; 5
Costongs (2019111617252500700_B19) 1985; 23
Petrylak (2019111617252500700_B8) 2006; 98
Neukirchen (2019111617252500700_B26) 2009; 83
Buckley (2019111617252500700_B20) 2000; 83
Garcia-Manero (2019111617252500700_B22) 2008; 22
Alhan (2019111617252500700_B3) 2016; 30
Malcovati (2019111617252500700_B12) 2005; 23
Zeidan (2019111617252500700_B29) 2014; 167
Ross (2019111617252500700_B21) 1988; 90
Greenberg (2019111617252500700_B2) 2012; 120
Nachtkamp (2019111617252500700_B24) 2016; 95
Ibrahim (2019111617252500700_B32) 2010; 28
de Swart (2019111617252500700_B9) 2015; 170
Zhao (2019111617252500700_B31) 2017; 12
Goldberg (2019111617252500700_B23) 2010; 28
Pereira (2019111617252500700_B30) 2011; 86
Sekeres (2019111617252500700_B27) 2008; 26
Bejar (2019111617252500700_B4) 2012; 30
Akaike (2019111617252500700_B15) 1974; 19
Grambsch (2019111617252500700_B16) 1994; 13
O’Brien (2019111617252500700_B17) 2007; 41
van der Helm (2019111617252500700_B28) 2011; 155
Greenberg (2019111617252500700_B1) 1997; 89
Pellagatti (2019111617252500700_B5) 2013; 31
Dayyani (2019111617252500700_B25) 2010; 116
Vardiman (2019111617252500700_B10) 2002; 100
Fine (2019111617252500700_B14) 1999; 94
References_xml – volume: 28
  start-page: 2796
  year: 2010
  end-page: 2801
  ident: bib32
  article-title: Basic concepts and methods for joint models of longitudinal and survival data
  publication-title: J Clin Oncol
– volume: 98
  start-page: 516
  year: 2006
  end-page: 521
  ident: bib8
  article-title: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
  publication-title: J Natl Cancer Inst
– volume: 95
  start-page: 937
  year: 2016
  end-page: 944
  ident: bib24
  article-title: Causes of death in 2877 patients with myelodysplastic syndromes
  publication-title: Ann Hematol
– volume: 170
  start-page: 372
  year: 2015
  end-page: 383
  ident: bib9
  article-title: Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
  publication-title: Br J Haematol
– volume: 30
  start-page: 658
  year: 2016
  end-page: 665
  ident: bib3
  article-title: The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system
  publication-title: Leukemia
– volume: 33
  start-page: 1
  year: 2010
  end-page: 22
  ident: bib18
  article-title: Regularization paths for generalized linear models via coordinate descent
  publication-title: J Stat Softw
– volume: 86
  start-page: 245
  year: 2011
  end-page: 250
  ident: bib30
  article-title: Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support
  publication-title: Am J Hematol
– volume: 26
  start-page: 5943
  year: 2008
  end-page: 5949
  ident: bib27
  article-title: Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes
  publication-title: J Clin Oncol
– volume: 28
  start-page: 2847
  year: 2010
  end-page: 2852
  ident: bib23
  article-title: Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
  publication-title: J Clin Oncol
– volume: 23
  start-page: 69
  year: 1985
  end-page: 76
  ident: bib19
  article-title: Short-term and long-term intra-individual variations and critical differences of haematological laboratory parameters
  publication-title: J Clin Chem Clin Biochem
– volume: 90
  start-page: 391
  year: 2005
  end-page: 399
  ident: bib7
  article-title: Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies
  publication-title: Haematologica
– volume: 90
  start-page: 262
  year: 1988
  end-page: 267
  ident: bib21
  article-title: Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation
  publication-title: Am J Clin Pathol
– volume: 96
  start-page: 1105
  year: 2017
  end-page: 1112
  ident: bib11
  article-title: Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
  publication-title: Ann Hematol
– volume: 94
  start-page: 496
  year: 1999
  end-page: 509
  ident: bib14
  article-title: A proportional hazards model for the subdistribution of a competing risk
  publication-title: J Am Stat Assoc
– volume: 83
  start-page: 477
  year: 2009
  end-page: 482
  ident: bib26
  article-title: Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes
  publication-title: Eur J Haematol
– volume: 31
  start-page: 3557
  year: 2013
  end-page: 3564
  ident: bib5
  article-title: Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes
  publication-title: J Clin Oncol
– volume: 13
  start-page: 1619
  year: 1994
  end-page: 1634
  ident: bib16
  article-title: Statistical analysis of proliferative index data in clinical trials
  publication-title: Stat Med
– volume: 22
  start-page: 538
  year: 2008
  end-page: 543
  ident: bib22
  article-title: A prognostic score for patients with lower risk myelodysplastic syndrome
  publication-title: Leukemia
– volume: 167
  start-page: 62
  year: 2014
  end-page: 68
  ident: bib29
  article-title: Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
  publication-title: Br J Haematol
– volume: 89
  start-page: 2079
  year: 1997
  end-page: 2088
  ident: bib1
  article-title: International scoring system for evaluating prognosis in myelodysplastic syndromes
  publication-title: Blood
– volume: 83
  start-page: 480
  year: 2000
  end-page: 484
  ident: bib20
  article-title: A novel approach to the assessment of variations in the human platelet count
  publication-title: Thromb Haemost
– volume: 116
  start-page: 2174
  year: 2010
  end-page: 2179
  ident: bib25
  article-title: Cause of death in patients with lower-risk myelodysplastic syndrome
  publication-title: Cancer
– volume: 155
  start-page: 599
  year: 2011
  end-page: 606
  ident: bib28
  article-title: Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
  publication-title: Br J Haematol
– volume: 25
  start-page: 3503
  year: 2007
  end-page: 3510
  ident: bib6
  article-title: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
  publication-title: J Clin Oncol
– volume: 41
  start-page: 673
  year: 2007
  end-page: 690
  ident: bib17
  article-title: A caution regarding rules of thumb for variance inflation factors
  publication-title: Qual Quant
– volume: 100
  start-page: 2292
  year: 2002
  end-page: 2302
  ident: bib10
  article-title: The World Health Organization (WHO) classification of the myeloid neoplasms
  publication-title: Blood
– volume: 30
  start-page: 3376
  year: 2012
  end-page: 3382
  ident: bib4
  article-title: Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
  publication-title: J Clin Oncol
– volume: 23
  start-page: 7594
  year: 2005
  end-page: 7603
  ident: bib12
  article-title: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
  publication-title: J Clin Oncol
– volume: 120
  start-page: 2454
  year: 2012
  end-page: 2465
  ident: bib2
  article-title: Revised international prognostic scoring system for myelodysplastic syndromes
  publication-title: Blood
– volume: 5
  start-page: 255
  year: 1986
  end-page: 260
  ident: bib13
  article-title: Censoring distributions as a measure of follow-up in survival analysis
  publication-title: Stat Med
– volume: 12
  start-page: e0180756
  year: 2017
  ident: bib31
  article-title: Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model
  publication-title: PLoS One
– volume: 19
  start-page: 716
  year: 1974
  end-page: 723
  ident: bib15
  article-title: A new look at the statistical model identification
  publication-title: IEEE Trans Automat Contr
– volume: 155
  start-page: 599
  issue: 5
  year: 2011
  ident: 2019111617252500700_B28
  article-title: Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2011.08893.x
– volume: 22
  start-page: 538
  issue: 3
  year: 2008
  ident: 2019111617252500700_B22
  article-title: A prognostic score for patients with lower risk myelodysplastic syndrome
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2405070
– volume: 41
  start-page: 673
  issue: 5
  year: 2007
  ident: 2019111617252500700_B17
  article-title: A caution regarding rules of thumb for variance inflation factors
  publication-title: Qual Quant
  doi: 10.1007/s11135-006-9018-6
– volume: 19
  start-page: 716
  issue: 6
  year: 1974
  ident: 2019111617252500700_B15
  article-title: A new look at the statistical model identification
  publication-title: IEEE Trans Automat Contr
  doi: 10.1109/TAC.1974.1100705
– volume: 83
  start-page: 477
  issue: 5
  year: 2009
  ident: 2019111617252500700_B26
  article-title: Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2009.01299.x
– volume: 120
  start-page: 2454
  issue: 12
  year: 2012
  ident: 2019111617252500700_B2
  article-title: Revised international prognostic scoring system for myelodysplastic syndromes
  publication-title: Blood
  doi: 10.1182/blood-2012-03-420489
– volume: 31
  start-page: 3557
  issue: 28
  year: 2013
  ident: 2019111617252500700_B5
  article-title: Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.45.5626
– volume: 89
  start-page: 2079
  issue: 6
  year: 1997
  ident: 2019111617252500700_B1
  article-title: International scoring system for evaluating prognosis in myelodysplastic syndromes
  publication-title: Blood
  doi: 10.1182/blood.V89.6.2079
– volume: 28
  start-page: 2796
  issue: 16
  year: 2010
  ident: 2019111617252500700_B32
  article-title: Basic concepts and methods for joint models of longitudinal and survival data
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.0654
– volume: 98
  start-page: 516
  issue: 8
  year: 2006
  ident: 2019111617252500700_B8
  article-title: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djj129
– volume: 100
  start-page: 2292
  issue: 7
  year: 2002
  ident: 2019111617252500700_B10
  article-title: The World Health Organization (WHO) classification of the myeloid neoplasms
  publication-title: Blood
  doi: 10.1182/blood-2002-04-1199
– volume: 5
  start-page: 255
  issue: 3
  year: 1986
  ident: 2019111617252500700_B13
  article-title: Censoring distributions as a measure of follow-up in survival analysis
  publication-title: Stat Med
  doi: 10.1002/sim.4780050306
– volume: 95
  start-page: 937
  issue: 6
  year: 2016
  ident: 2019111617252500700_B24
  article-title: Causes of death in 2877 patients with myelodysplastic syndromes
  publication-title: Ann Hematol
  doi: 10.1007/s00277-016-2649-3
– volume: 13
  start-page: 1619
  issue: 16
  year: 1994
  ident: 2019111617252500700_B16
  article-title: Statistical analysis of proliferative index data in clinical trials
  publication-title: Stat Med
  doi: 10.1002/sim.4780131603
– volume: 30
  start-page: 658
  issue: 3
  year: 2016
  ident: 2019111617252500700_B3
  article-title: The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system
  publication-title: Leukemia
  doi: 10.1038/leu.2015.295
– volume: 28
  start-page: 2847
  issue: 17
  year: 2010
  ident: 2019111617252500700_B23
  article-title: Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.2395
– volume: 26
  start-page: 5943
  issue: 36
  year: 2008
  ident: 2019111617252500700_B27
  article-title: Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.5770
– volume: 170
  start-page: 372
  issue: 3
  year: 2015
  ident: 2019111617252500700_B9
  article-title: Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
  publication-title: Br J Haematol
  doi: 10.1111/bjh.13450
– volume: 12
  start-page: e0180756
  issue: 7
  year: 2017
  ident: 2019111617252500700_B31
  article-title: Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0180756
– volume: 94
  start-page: 496
  issue: 446
  year: 1999
  ident: 2019111617252500700_B14
  article-title: A proportional hazards model for the subdistribution of a competing risk
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1999.10474144
– volume: 96
  start-page: 1105
  issue: 7
  year: 2017
  ident: 2019111617252500700_B11
  article-title: Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
  publication-title: Ann Hematol
  doi: 10.1007/s00277-017-3009-7
– volume: 23
  start-page: 7594
  issue: 30
  year: 2005
  ident: 2019111617252500700_B12
  article-title: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.01.7038
– volume: 90
  start-page: 262
  issue: 3
  year: 1988
  ident: 2019111617252500700_B21
  article-title: Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation
  publication-title: Am J Clin Pathol
  doi: 10.1093/ajcp/90.3.262
– volume: 167
  start-page: 62
  issue: 1
  year: 2014
  ident: 2019111617252500700_B29
  article-title: Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
  publication-title: Br J Haematol
  doi: 10.1111/bjh.13008
– volume: 90
  start-page: 391
  issue: 3
  year: 2005
  ident: 2019111617252500700_B7
  article-title: Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies
  publication-title: Haematologica
– volume: 33
  start-page: 1
  issue: 1
  year: 2010
  ident: 2019111617252500700_B18
  article-title: Regularization paths for generalized linear models via coordinate descent
  publication-title: J Stat Softw
  doi: 10.18637/jss.v033.i01
– volume: 25
  start-page: 3503
  issue: 23
  year: 2007
  ident: 2019111617252500700_B6
  article-title: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.5696
– volume: 30
  start-page: 3376
  issue: 27
  year: 2012
  ident: 2019111617252500700_B4
  article-title: Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.40.7379
– volume: 23
  start-page: 69
  issue: 2
  year: 1985
  ident: 2019111617252500700_B19
  article-title: Short-term and long-term intra-individual variations and critical differences of haematological laboratory parameters
  publication-title: J Clin Chem Clin Biochem
– volume: 83
  start-page: 480
  issue: 3
  year: 2000
  ident: 2019111617252500700_B20
  article-title: A novel approach to the assessment of variations in the human platelet count
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1613840
– volume: 116
  start-page: 2174
  issue: 9
  year: 2010
  ident: 2019111617252500700_B25
  article-title: Cause of death in patients with lower-risk myelodysplastic syndrome
  publication-title: Cancer
  doi: 10.1002/cncr.24984
– volume: 86
  start-page: 245
  issue: 3
  year: 2011
  ident: 2019111617252500700_B30
  article-title: Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support
  publication-title: Am J Hematol
  doi: 10.1002/ajh.21959
SSID ssj0001763592
Score 2.1498554
Snippet Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on...
A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS. Platelet drop combined with RBC-TD...
A drop in platelet count >25% relative to baseline at 6 months from diagnosis predicts inferior outcome in lower-risk MDS. Platelet drop combined with RBC-TD...
SourceID doaj
swepub
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2079
SubjectTerms Myeloid Neoplasia
Title Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2473952920308855
https://dx.doi.org/10.1182/bloodadvances.2018020495
https://www.ncbi.nlm.nih.gov/pubmed/30126931
https://www.proquest.com/docview/2091239697
https://pubmed.ncbi.nlm.nih.gov/PMC6113605
http://kipublications.ki.se/Default.aspx?queryparsed=id:142611425
https://doaj.org/article/4d3ba627400747e48265a56eee12eb2b
Volume 2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTlyqImi75SEjVdwsEr9iqydAIFSpnEBCvUR-RazYZhG7HPj3nXGShYgDe-AWJZ4knhnb3ziTbwj5yV3VxIZrxlMwTPpUMReCYjqVHlbPKshcG_DPlb68kb9v1e2rUl-YE9bRA3eKO5ZReIcFYjLVe5IAh5VTOqVUcogKPc6-hS1eBVN5dwV51nJFZC4rwazidkjjMfw454T339iRshtZ0AApq9HalCn8R0vUWwj6NpNyxDea16iLL-RzDy7pSdepLfIptdvkb-Ywpg8zQJVgJJqrQ9B7QJfI0Ezv3IJiklY7R8ZmiuTfiU5bOsPyaQwzz-m_5zSbx-cF3CK3GVgOFjvk5uL8-uyS9RUVWKgKvWTSOiW8UVpEwU30oWgAH0RZRYhTI47vDEnKwJVJRoGKhZMNICwTTONLJ76SjXbepu-E8sgbH4RyyXEIsR1EboUEHRpwCpCoJqQadFmHnm4cq17M6hx2GF6PrFC_WGFCypXkQ0e5sYbMKZpr1R5Js_MJcKW6d6X6PVeaEDsYux7-S4WZFG40XeMFfq1ke-zSYZI1pQ8H36pheOM3G9em-RO2sWAEqy0o9Fvna6tOwtzMtRUlqHrkhSMtjK-007tMIa6xlE8Bzz3q_HUk0p-6hyNQmtGl1j8-Qr-7ZBO7jDvy3OyRjeXjU9oHSLf0B3n0_gfFl0wg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+platelet+count+kinetics+has+prognostic+value+in+lower-risk+myelodysplastic+syndromes&rft.jtitle=Blood+advances&rft.au=Itzykson%2C+Raphael&rft.au=Crouch%2C+Simon&rft.au=Travaglino%2C+Erica&rft.au=Smith%2C+Alex&rft.date=2018-08-28&rft.pub=Elsevier+Inc&rft.issn=2473-9529&rft.volume=2&rft.issue=16&rft.spage=2079&rft.epage=2089&rft_id=info:doi/10.1182%2Fbloodadvances.2018020495&rft.externalDocID=S2473952920308855
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2473-9529&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2473-9529&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2473-9529&client=summon